Human Fibrinogen ELISA Kit (DEIA2222)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
cell biological samples
Species Reactivity
Human
Intended Use
The Fibrinogen test kits is for measuring Fibrinogen in biological samples of humans.
Contents of Kit
1. Diluent Concentrate ( Running Buffer )
2. Wash Solution Concentrate
3. Enzyme-Antibody Conjugate 100X
4. Chromogen-Substrate Solution
5. Stop Solution
6. Anti-Human Fibrinogen ELISA Microplate
7. Human Fibrinogen Calibrator
Storage
Store all contents at 2-8°C, except Human Fibrinogen Calibrator at 4°C. For more detailed information, please download the following document on our website.
Detection Range
12.5-400 ng/mL

Citations


Have you cited DEIA2222 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Effect of forming-gas annealing on the resistance switching effect of heteroepitaxial Nb:SrTiO3 film on Si substrate

APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING

Authors: Xiang, Wenfeng; Hu, Minghao; Liu, Yi

The influence of forming-gas annealing (FGA) on the resistance switching effect of epitaxial Nb:SrTiO3 [Nb-doped strontium titanates (NbSTO)] films on Si substrate has been investigated. The resistance values at low and high resistance states for NbSTO films after FGA are about two orders of magnitude lower than those of the as-deposited sample, which may effectively decrease the power dissipation of devices. Hysteretic I-V characteristic curves show that the stability of FGA sample was improved. The resistance ratio of NbSTO films measured via pulse voltage increased from 1.0-1.2 to 3.2-3.6 after FGA. Moreover, the resistance ratio of the FGA sample gradually increased with increasing number of cycles. These results indicate that FGA improves the resistance switching characteristics of NbSTO films. In addition, the underlying mechanism was discussed.

Management of Acute Agitation and Aggression in Children and Adolescents with Pro Re Nata Oral Immediate Release Antipsychotics in the Pediatric Emergency Department

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Authors: Yip, Lisa; Aeng, Elissa; Elbe, Dean

Background:Acute agitation in the pediatric emergency department (ED) has the potential to escalate into aggression and result in harm. Rapid and effective management may be warranted. Use of pro re nata (prn) oral immediate-release (IR) quetiapine, haloperidol, loxapine, and chlorpromazine has been observed in the pediatric ED at Surrey Memorial Hospital to manage this condition; however, evidence for oral prn antipsychotic use is limited in the pediatric population. Objectives:The primary objective is to characterize the dose of prn oral IR quetiapine used to manage acute agitation or aggression in a pediatric ED. Secondary objectives include characterizing the dose of prn oral IR haloperidol, loxapine, and chlorpromazine; and describing the 1-hour response rate, admission rate, length of stay (LOS), and adverse drug effects. Method:The medical records of pediatric patients who received at least one prn oral dose of IR quetiapine, haloperidol, loxapine, or chlorpromazine for acute agitation and aggression, without regard to the etiology of symptom presentation, between January 1, 2012 and December 31, 2016, were analyzed retrospectively. Results:Sixty-nine patients met the inclusion criteria. The mean dose of quetiapine was 32 mg/dose (0.54 mg/kg per dose); and the response rate was 53%. The mean haloperidol, loxapine, and chlorpromazine doses were 4 mg (0.07 mg/kg per dose), 13 mg (0.19 mg/kg per dose), and 29 mg/dose (0.53 mg/kg per dose) respectively; and the response rates were 36%, 30%, and 50%, respectively. Between 19% and 60% of patients were admitted, majority to the psychiatry ward. The median LOS in the ED was between 5 and 18 hours for nonadmitted patients. Extrapyramidal side effects (EPS) were reported with first-generation antipsychotics (FGA), but not with quetiapine. Conclusion:Quetiapine appears to be a viable agent for managing acute agitation and aggression in the pediatric ED with low rates of EPS. Further studies are encouraged to compare the effectiveness of quetiapine with FGA. A Clinical Trial Registration number is not applicable for this study.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket